The cytochrome P450 isoenzyme and some new opportunities for the prediction of negative drug interaction in vivo

Dmitrij A Sychev,1 Ghulam Md Ashraf,2 Andrey A Svistunov,3 Maksim L Maksimov,4 Vadim V Tarasov,3 Vladimir N Chubarev,3 Vitalij A Otdelenov,1 Natal’ja P Denisenko,1 George E Barreto,5,6 Gjumrakch Aliev7–9 1Russian Medical Academy of Postgraduate Education Studies, Moscow, Russia;...

Full description

Bibliographic Details
Main Authors: Sychev DA, Ashraf GM, Svistunov AA, Maksimov ML, Tarasov VV, Chubarev VN, Otdelenov VA, Denisenko NP, Barreto GE, Aliev G
Format: Article
Language:English
Published: Dove Medical Press 2018-05-01
Series:Drug Design, Development and Therapy
Subjects:
Online Access:https://www.dovepress.com/the-cytochrome-p450-isoenzyme-and-some-new-opportunities-for-the-predi-peer-reviewed-article-DDDT
id doaj-084a5e689b81484c82b063dd7653eb8c
record_format Article
spelling doaj-084a5e689b81484c82b063dd7653eb8c2020-11-24T22:45:53ZengDove Medical PressDrug Design, Development and Therapy1177-88812018-05-01Volume 121147115638189The cytochrome P450 isoenzyme and some new opportunities for the prediction of negative drug interaction in vivoSychev DAAshraf GMSvistunov AAMaksimov MLTarasov VVChubarev VNOtdelenov VADenisenko NPBarreto GEAliev GDmitrij A Sychev,1 Ghulam Md Ashraf,2 Andrey A Svistunov,3 Maksim L Maksimov,4 Vadim V Tarasov,3 Vladimir N Chubarev,3 Vitalij A Otdelenov,1 Natal’ja P Denisenko,1 George E Barreto,5,6 Gjumrakch Aliev7–9 1Russian Medical Academy of Postgraduate Education Studies, Moscow, Russia; 2King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia; 3Sechenov First Moscow State Medical University, Moscow, Russia; 4Branch Campus of the Federal State Budgetary Educational Institution of Further Professional Education «Russian Medical Academy of Continuous Professional Education» of the Ministry of Healthcare of the Russian Federation, Kazan State Medical Academy, Volga Region, Kazan, Russia; 5Departamento de Nutrición y Bioquímica, Facultad de Ciencias, Pontificia Universidad Javeriana, Bogotá D.C., Colombia; 6Instituto de Ciencias Biomédicas, Universidad Autónoma de Chile, Santiago, Chile; 7GALLY International Biomedical Research Consulting LLC, San Antonio, TX, USA; 8School of Health Science and Healthcare Administration, University of Atlanta, Johns Creek, GA, USA; 9Institute of Physiologically Active Compounds Russian Academy of Sciences, Chernogolovka, Russia Abstract: Cytochrome (CYP) 450 isoenzymes are the basic enzymes involved in Phase I biotransformation. The most important role in biotransformation belongs to CYP3A4, CYP2D6, CYP2C9, CYP2C19 and CYP1A2. Inhibition and induction of CYP isoenzymes caused by drugs are important and clinically relevant pharmacokinetic mechanisms of drug interaction. Investigation of the activity of CYP isoenzymes by using phenotyping methods (such as the determination of the concentration of specific substrates and metabolites in biological fluids) during drug administration provides the prediction of negative side effects caused by drug interaction. In clinical practice, the process of phenotyping of CYP isoenzymes and some endogenous substrates in the ratio of cortisol to 6β-hydroxycortisol in urine for the evaluation of CYP3A4 activity has been deemed to be a quite promising, safe and minimally invasive method for patients nowadays. Keywords: cytochrome CYP450, drug interaction, drug metabolism, phenotypinghttps://www.dovepress.com/the-cytochrome-p450-isoenzyme-and-some-new-opportunities-for-the-predi-peer-reviewed-article-DDDTCytochrome CYP-450Drug interactionDrug metabolismPhenotyping;
collection DOAJ
language English
format Article
sources DOAJ
author Sychev DA
Ashraf GM
Svistunov AA
Maksimov ML
Tarasov VV
Chubarev VN
Otdelenov VA
Denisenko NP
Barreto GE
Aliev G
spellingShingle Sychev DA
Ashraf GM
Svistunov AA
Maksimov ML
Tarasov VV
Chubarev VN
Otdelenov VA
Denisenko NP
Barreto GE
Aliev G
The cytochrome P450 isoenzyme and some new opportunities for the prediction of negative drug interaction in vivo
Drug Design, Development and Therapy
Cytochrome CYP-450
Drug interaction
Drug metabolism
Phenotyping;
author_facet Sychev DA
Ashraf GM
Svistunov AA
Maksimov ML
Tarasov VV
Chubarev VN
Otdelenov VA
Denisenko NP
Barreto GE
Aliev G
author_sort Sychev DA
title The cytochrome P450 isoenzyme and some new opportunities for the prediction of negative drug interaction in vivo
title_short The cytochrome P450 isoenzyme and some new opportunities for the prediction of negative drug interaction in vivo
title_full The cytochrome P450 isoenzyme and some new opportunities for the prediction of negative drug interaction in vivo
title_fullStr The cytochrome P450 isoenzyme and some new opportunities for the prediction of negative drug interaction in vivo
title_full_unstemmed The cytochrome P450 isoenzyme and some new opportunities for the prediction of negative drug interaction in vivo
title_sort cytochrome p450 isoenzyme and some new opportunities for the prediction of negative drug interaction in vivo
publisher Dove Medical Press
series Drug Design, Development and Therapy
issn 1177-8881
publishDate 2018-05-01
description Dmitrij A Sychev,1 Ghulam Md Ashraf,2 Andrey A Svistunov,3 Maksim L Maksimov,4 Vadim V Tarasov,3 Vladimir N Chubarev,3 Vitalij A Otdelenov,1 Natal’ja P Denisenko,1 George E Barreto,5,6 Gjumrakch Aliev7–9 1Russian Medical Academy of Postgraduate Education Studies, Moscow, Russia; 2King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia; 3Sechenov First Moscow State Medical University, Moscow, Russia; 4Branch Campus of the Federal State Budgetary Educational Institution of Further Professional Education «Russian Medical Academy of Continuous Professional Education» of the Ministry of Healthcare of the Russian Federation, Kazan State Medical Academy, Volga Region, Kazan, Russia; 5Departamento de Nutrición y Bioquímica, Facultad de Ciencias, Pontificia Universidad Javeriana, Bogotá D.C., Colombia; 6Instituto de Ciencias Biomédicas, Universidad Autónoma de Chile, Santiago, Chile; 7GALLY International Biomedical Research Consulting LLC, San Antonio, TX, USA; 8School of Health Science and Healthcare Administration, University of Atlanta, Johns Creek, GA, USA; 9Institute of Physiologically Active Compounds Russian Academy of Sciences, Chernogolovka, Russia Abstract: Cytochrome (CYP) 450 isoenzymes are the basic enzymes involved in Phase I biotransformation. The most important role in biotransformation belongs to CYP3A4, CYP2D6, CYP2C9, CYP2C19 and CYP1A2. Inhibition and induction of CYP isoenzymes caused by drugs are important and clinically relevant pharmacokinetic mechanisms of drug interaction. Investigation of the activity of CYP isoenzymes by using phenotyping methods (such as the determination of the concentration of specific substrates and metabolites in biological fluids) during drug administration provides the prediction of negative side effects caused by drug interaction. In clinical practice, the process of phenotyping of CYP isoenzymes and some endogenous substrates in the ratio of cortisol to 6β-hydroxycortisol in urine for the evaluation of CYP3A4 activity has been deemed to be a quite promising, safe and minimally invasive method for patients nowadays. Keywords: cytochrome CYP450, drug interaction, drug metabolism, phenotyping
topic Cytochrome CYP-450
Drug interaction
Drug metabolism
Phenotyping;
url https://www.dovepress.com/the-cytochrome-p450-isoenzyme-and-some-new-opportunities-for-the-predi-peer-reviewed-article-DDDT
work_keys_str_mv AT sychevda thecytochromep450isoenzymeandsomenewopportunitiesforthepredictionofnegativedruginteractioninvivo
AT ashrafgm thecytochromep450isoenzymeandsomenewopportunitiesforthepredictionofnegativedruginteractioninvivo
AT svistunovaa thecytochromep450isoenzymeandsomenewopportunitiesforthepredictionofnegativedruginteractioninvivo
AT maksimovml thecytochromep450isoenzymeandsomenewopportunitiesforthepredictionofnegativedruginteractioninvivo
AT tarasovvv thecytochromep450isoenzymeandsomenewopportunitiesforthepredictionofnegativedruginteractioninvivo
AT chubarevvn thecytochromep450isoenzymeandsomenewopportunitiesforthepredictionofnegativedruginteractioninvivo
AT otdelenovva thecytochromep450isoenzymeandsomenewopportunitiesforthepredictionofnegativedruginteractioninvivo
AT denisenkonp thecytochromep450isoenzymeandsomenewopportunitiesforthepredictionofnegativedruginteractioninvivo
AT barretoge thecytochromep450isoenzymeandsomenewopportunitiesforthepredictionofnegativedruginteractioninvivo
AT alievg thecytochromep450isoenzymeandsomenewopportunitiesforthepredictionofnegativedruginteractioninvivo
AT sychevda cytochromep450isoenzymeandsomenewopportunitiesforthepredictionofnegativedruginteractioninvivo
AT ashrafgm cytochromep450isoenzymeandsomenewopportunitiesforthepredictionofnegativedruginteractioninvivo
AT svistunovaa cytochromep450isoenzymeandsomenewopportunitiesforthepredictionofnegativedruginteractioninvivo
AT maksimovml cytochromep450isoenzymeandsomenewopportunitiesforthepredictionofnegativedruginteractioninvivo
AT tarasovvv cytochromep450isoenzymeandsomenewopportunitiesforthepredictionofnegativedruginteractioninvivo
AT chubarevvn cytochromep450isoenzymeandsomenewopportunitiesforthepredictionofnegativedruginteractioninvivo
AT otdelenovva cytochromep450isoenzymeandsomenewopportunitiesforthepredictionofnegativedruginteractioninvivo
AT denisenkonp cytochromep450isoenzymeandsomenewopportunitiesforthepredictionofnegativedruginteractioninvivo
AT barretoge cytochromep450isoenzymeandsomenewopportunitiesforthepredictionofnegativedruginteractioninvivo
AT alievg cytochromep450isoenzymeandsomenewopportunitiesforthepredictionofnegativedruginteractioninvivo
_version_ 1725687149560332288